- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Eterna Therapeutics Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| Di | Eterna Therapeutics-Aktionär Charles Cherington verkauft Aktien im Wert von 6,54 Millionen US-Dollar | - | Investing.com Deutsch | ||
| 30.10. | Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success | 49 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) ("Eterna" or the "Company") today announced the successful completion of a comprehensive financial restructuring... ► Artikel lesen | |
| 29.10. | Eterna Therapeutics announces share issuance and executive agreements | 1 | Investing.com | ||
| 29.10. | Eterna Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.10. | Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases | 89 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) ("Eterna" or the "Company") and Factor Bioscience Limited ("Factor") today announced an exclusive license... ► Artikel lesen | |
| 27.09. | Eterna Therapeutics inks new license agreement, ends previous Factor Bioscience deals | 1 | Investing.com | ||
| 23.09. | Eterna Therapeutics droht Delisting von der Nasdaq aufgrund von Eigenkapitalmangel | 1 | Investing.com Deutsch | ||
| 23.09. | Eterna Therapeutics faces Nasdaq delisting over equity shortfall | 1 | Investing.com | ||
| 23.09. | Eterna Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.08. | Eterna Therapeutics Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 13.08. | Eterna Therapeutics Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.05. | Eterna Therapeutics Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 20.12.23 | Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer | 233 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 0,900 | +11,66 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,398 | +3,65 % | Defence Therapeutics meldet Verlängerung der Privatplatzierung und setzt die Entwicklung seiner Radiopharmazeutika- und ADC-Programme fort | Vancouver, BC, Kanada, 4. November 2024 / IRW-Press / Defence Therapeutics Inc. ("Defence" oder das
"Unternehmen") (CSE: DTC, OTCQB: DTCFF, FWB: DTC), ein kanadisches biopharmazeutisches Unternehmen... ► Artikel lesen | |
| GINKGO BIOWORKS | 7,750 | 0,00 % | Lesaffre strengthens its Research, Development & Innovation (RD&I) with the acquisition of Altar, a company owned by Ginkgo Bioworks | MARCQ-EN-BARŒUL, France, Oct. 7, 2024 /PRNewswire/ -- Lesaffre, a key global player in the field of fermentation and microorganisms, announces the acquisition of Altar, a French start-up... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,980 | +0,72 % | Recursion Pharmaceuticals EPS of -$0.34 misses by $0.01, revenue of $26.1M misses by $3.73M | ||
| BEAM THERAPEUTICS | 26,820 | +2,80 % | Beam Therapeutics Inc. Q3 Loss Misses Estimates | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) reported Loss for third quarter that missed the Street estimates.The company's earnings came in at -$96.668 million, or -$1.17 per share.... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,990 | -1,00 % | Oncolytics Biotech Inc.: Oncolytics Biotech Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study | Overall survival (OS) results from BRACELET-1 corroborate results of previous randomized IND-213 breast cancer study
Together, these two studies support the compelling potential of pelareorep-based... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 19,560 | +4,38 % | Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious... ► Artikel lesen | |
| ASSERTIO | 0,970 | -3,96 % | Assertio sieht sich Betrugsvorwürfen gegenüber, Investor geht Short-Position ein | ||
| SIGA TECHNOLOGIES | 7,560 | -0,92 % | SIGA TECHNOLOGIES INC - 10-Q, Quarterly Report | ||
| ADMA BIOLOGICS | 22,870 | +15,97 % | ADMA Biologics-Aktie erreicht Allzeithoch von 21,25 US-Dollar | ||
| VIR BIOTECHNOLOGY | 9,710 | -0,61 % | VIR Biotechnology's SWOT analysis: stock poised for growth amid challenges | ||
| MERRIMACK PHARMACEUTICALS | 15,130 | 0,00 % | Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") announced that the stockholders at a Special Meeting held today overwhelmingly approved... ► Artikel lesen | |
| VERVE THERAPEUTICS | 6,330 | -0,47 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31, 2024... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 16,000 | -2,44 % | Travere Therapeutics prices $125M equity offering | ||
| ARVINAS | 27,970 | +0,79 % | Arvinas's SWOT analysis: biotech stock poised for pivotal trial results |
ETERNA THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,020 (-1,80 %) liegt der Kurs bei 1,090 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ETERNA THERAPEUTICS INC finden Sie auf Wallstreet Online.
